Literature DB >> 16027765

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Maurizio Fava1, A John Rush, Michael E Thase, Anita Clayton, Stephen M Stahl, James F Pradko, J Andrew Johnston.   

Abstract

BACKGROUND: Bupropion has been available in the United States since 1989. Initially a thrice-daily immediate-release formulation, a twice-daily sustained-release formulation followed in 1996, and, in August 2003, a once-daily extended-release formulation was introduced. On the 15th anniversary of its introduction, we undertook a review of the background/history, mechanism of action, formulations, and clinical profile of bupropion. DATA SOURCES: Major efficacy trials and other reports were obtained and reviewed from MEDLINE searches, review of abstracts from professional meetings, and the bupropion SR manufacturer's databases. Searches of English-language articles were conducted from June 2003 through August 2004. No time limit was specified in the searches, which were conducted using the search terms bupropion, bupropion SR, and bupropion XL. DATA SYNTHESIS: Bupropion inhibits the re-uptake of norepinephrine and dopamine neurotransmission without any significant direct effects on serotonin neurotransmission. Bupropion is an effective antidepressant with efficacy comparable to selective serotonin reuptake inhibitors and other antidepressants. It is well tolerated in short-and longer-term treatment. Headache, dry mouth, nausea, insomnia, constipation, and dizziness are the most common adverse events. Seizure and allergic reactions are medically important adverse events associated with bupropion and are reported rarely. Among all the newer antidepressants in the United States, bupropion appears to have among the lowest incidence of sexual dysfunction, weight gain, and somnolence. Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents.
CONCLUSION: Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.

Entities:  

Year:  2005        PMID: 16027765      PMCID: PMC1163271          DOI: 10.4088/pcc.v07n0305

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  60 in total

1.  Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.

Authors:  C C Coleman; L A Cunningham; V J Foster; S R Batey; R M Donahue; T L Houser; J A Ascher
Journal:  Ann Clin Psychiatry       Date:  1999-12       Impact factor: 1.567

2.  A comparative study of bupropion and amitriptyline in depressed outpatients.

Authors:  J Mendels; M M Amin; G Chouinard; A J Cooper; J E Miles; R A Remick; B Saxena; S K Secunda; A N Singh
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

3.  Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

Authors:  R J Kavoussi; R T Segraves; A R Hughes; J A Ascher; J A Johnston
Journal:  J Clin Psychiatry       Date:  1997-12       Impact factor: 4.384

4.  Safety profile of sustained-release bupropion in depression: results of three clinical trials.

Authors:  E C Settle; S M Stahl; S R Batey; J A Johnston; J A Ascher
Journal:  Clin Ther       Date:  1999-03       Impact factor: 3.393

5.  Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.

Authors:  Harry Croft; Trisha L Houser; Brenda D Jamerson; Robert Leadbetter; Carolyn Bolden-Watson; Rafe Donahue; Alan Metz
Journal:  Clin Ther       Date:  2002-04       Impact factor: 3.393

6.  In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography.

Authors:  Susan M Learned-Coughlin; Mats Bergström; Irina Savitcheva; John Ascher; Virginia D Schmith; Bengt Långstrom
Journal:  Biol Psychiatry       Date:  2003-10-15       Impact factor: 13.382

Review 7.  Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience.

Authors:  L Ferry; J A Johnston
Journal:  Int J Clin Pract       Date:  2003-04       Impact factor: 2.503

8.  Double-blind comparison of bupropion and fluoxetine in depressed outpatients.

Authors:  J P Feighner; E A Gardner; J A Johnston; S R Batey; M A Khayrallah; J A Ascher; C G Lineberry
Journal:  J Clin Psychiatry       Date:  1991-08       Impact factor: 4.384

9.  Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.

Authors:  G Wright; L Galloway; J Kim; M Dalton; L Miller; W Stern
Journal:  J Clin Psychiatry       Date:  1985-01       Impact factor: 4.384

10.  Efficacy of bupropion in tricyclic-resistant or intolerant patients.

Authors:  W C Stern; N Harto-Truax; N Bauer
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

View more
  77 in total

1.  Bupropion-Induced Stuttering.

Authors:  Manjeet S Bhatia
Journal:  Prim Care Companion CNS Disord       Date:  2015-08-13

Review 2.  A clinical prescription for heart health in midlife women.

Authors:  Chrisandra Shufelt; Erika Dutra; Tina Torbati; Tina Ramineni
Journal:  Maturitas       Date:  2018-11-12       Impact factor: 4.342

3.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

4.  Metabolism of bupropion by carbonyl reductases in liver and intestine.

Authors:  Jamie N Connarn; Xinyuan Zhang; Andrew Babiskin; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2015-04-22       Impact factor: 3.922

5.  Effects of bupropion sustained release on task-related EEG alpha activity in smokers: Individual differences in drug response.

Authors:  Jian Zhu; Ryan P Coppens; Norka E Rabinovich; David G Gilbert
Journal:  Exp Clin Psychopharmacol       Date:  2017-02       Impact factor: 3.157

Review 6.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

7.  Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans.

Authors:  Jennifer E Sager; John R Choiniere; Justine Chang; Alyssa Stephenson-Famy; Wendel L Nelson; Nina Isoherranen
Journal:  ACS Med Chem Lett       Date:  2016-06-17       Impact factor: 4.345

8.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

Review 9.  The role of dopaminergic agents in improving quality of life in major depressive disorder.

Authors:  Waguih William IsHak; Michael Davis; Jessica Jeffrey; Konstantin Balayan; Robert N Pechnick; Kara Bagot; Mark Hyman Rapaport
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

10.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.